Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- AVTE
- Price
- 3283.00
- Stock movement up
- +- (%)
- Company name
- Aerovate Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.71B
- Ent value
- 2.69B
- Price/Sales
- 19939.47
- Price/Book
- 33.69
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 342.45%
- 3 year return
- 84.56%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-05-29
DIVIDENDS
AVTE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 19939.47 |
| Price to Book | 33.69 |
| EV to Sales | 19787.64 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 826.00K |
| EPS (TTM) | -102.60 |
| FCF per share (TTM) | -90.96 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 136.00K |
| Gross profit (TTM) | 52.00K |
| Operating income (TTM) | -90.26M |
| Net income (TTM) | -84.61M |
| EPS (TTM) | -102.60 |
| EPS (1y forward) | -16.27 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 38.24% |
| Operating margin (TTM) | -66366.91% |
| Profit margin (TTM) | -62213.97% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 31.11M |
| Net receivables | 0.00 |
| Total current assets | 90.61M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 90.96M |
| Accounts payable | 908.00K |
| Short/Current long term debt | 540.00K |
| Total current liabilities | 10.31M |
| Total liabilities | 10.47M |
| Shareholder's equity | 80.49M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -74.95M |
| Capital expenditures (TTM) | 64.00K |
| Free cash flow (TTM) | -75.01M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -105.12% |
| Return on Assets | -93.02% |
| Return on Invested Capital | -104.52% |
| Cash Return on Invested Capital | -92.66% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 3258.50 |
| Daily high | 3393.25 |
| Daily low | 3221.26 |
| Daily Volume | 29K |
| All-time high | 3356.50 |
| 1y analyst estimate | 81.67 |
| Beta | 1.00 |
| EPS (TTM) | -102.60 |
| Dividend per share | - |
| Ex-div date | 29 Apr 2025 |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| AVTE | S&P500 | |
| Current price drop from All-time high | -2.19% | -10.13% |
| Highest price drop | -95.41% | -56.47% |
| Date of highest drop | 18 Jun 2024 | 9 Mar 2009 |
| Avg drop from high | -47.29% | -11.06% |
| Avg time to new high | 60 days | 12 days |
| Max time to new high | 325 days | 1805 days |
COMPANY DETAILS
Marketcap
2.71B
Marketcap category
Mid-cap
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Employees
51
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner